Cellular Origins agreed to collaborate with Immatics to use the companies’ shared automated manufacturing capabilities, incorporating Cellular Origins’ Constellation mobile robotic platform into parts of Immatics’ cell therapy process. The work is intended to test whether automation can improve efficiency and scalability for next-generation cell therapies. Immatics said it is advancing clinically validated approaches that could expand treatment options for solid tumors, where manufacturing bottlenecks have limited patient access. Cellular Origins’ CEO Edwin Stone cited how manual manufacturing can cap the number of patients who receive approved therapies. Immatics highlighted that its precision targeting PRAME platform spans more than 50 cancers, and said the partnership is aligned with efforts to build manufacturing capacity ahead of potential approvals. The collaboration focuses on process integration rather than new clinical trials, emphasizing a CMC-driven push to scale cell therapy supply.